Company Analysis

Vanda Pharmaceuticals Inc. (VNDA)

Nasdaq: VNDA · Pharmaceutical Preparations · Washington, DC · filing with the SEC since 2005
Grade6.0
◀ Past 7.4● Present 6.0▶ Future 4.5
1 est.

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016
Report filedFeb 12, 2026Feb 14, 2025Feb 8, 2024Feb 9, 2023Feb 24, 2022Feb 11, 2021Feb 26, 2020Feb 19, 2019Feb 15, 2018Feb 17, 2017
Revenue216,105198,772192,640254,382268,682248,168227,188193,118165,083146,017
Cost of revenue13,04411,31414,79624,28225,62923,36424,48820,508··
Research and development109,27174,43176,82385,77075,36355,57748,64943,59438,54729,156
Selling, general and administrative237,951146,414112,883136,485124,047140,510129,736105,751123,84199,787
Total costs and expenses367,273239,432206,592248,053226,517220,929204,378171,380181,986164,588
Operating income-151,168-40,660-13,9526,32942,16527,23922,81021,738-16,903-18,571
Income before income taxes-138,647-22,9216,33911,30042,36431,65529,02825,346-15,431-17,906
Income tax expense81,827-4,0213,8305,0259,2128,318-86,525138136104
Net income-220,474-18,9002,5096,27533,15223,337115,55325,208-15,567-18,010
Earnings per share, basic-3.74-0.330.040.110.600.432.170.50-0.35-0.41
Earnings per share, diluted-3.74-0.330.040.110.580.422.110.48-0.35-0.41
Weighted average shares, basic58,930,15758,149,08757,380,97556,461,87755,548,12254,427,68353,137,56250,859,94744,735,14643,449,441
Weighted average shares, diluted58,930,15758,149,08757,557,91156,983,17156,921,83655,190,80254,847,06053,045,25744,735,14643,449,441
Weighted average shares, basic and diluted········44,735,14643,449,441
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:Revenues
Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense
Total costs and expenses every operating cost, the cost of revenue includedus-gaap:CostsAndExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton VNDA · research, not advice